NCT04843631View on ClinicalTrials.gov

Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 8, 2021

Study Completion Date

December 8, 2021

Conditions

Psoriasis

Interventions

DRUG

BFI-751

Single use vial, solution

DRUG

EU-STELARA®

Pre-filled syringe, solution

DRUG

US-STELARA®

Pre-filled syringe, solution

Trial Locations (3)

1010

NZCR, Grafton

4029

Nucleus Network, Brisbane

5000

CMAX, Adelaide

Sponsors

Collaborators (1)

Avance Clinical Pty Ltd.

All Listed Sponsors

collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

BioFactura Australia Pty Ltd.

INDUSTRY